We are united in our efforts to provide patients with reasons to believe that they can receive effective treatments while carrying on with their daily living.
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
AVEO’s strategy is to grow into a global oncology leader through the development and commercialization of its current pipeline programs and the acquisition of additional innovative programs.
AVEO’s lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma (UK) Limited (a Recordati Group Company) for the treatment of adult patients with advanced RCC.
AVEO has previously reported promising phase 2 clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck squamous cell carcinoma (HNSCC), pancreatic cancer and acute myeloid leukemia.
AVEO has initiated a multicenter, randomized, double blind, placebo-controlled, phase 3 clinical trial of ficlatuzumab in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (FIERCE-HN). AVEO expects to begin enrollment in the FIERCE-HN clinical trial in the fourth quarter of 2023. (For more information go to clinicaltrials.gov)
AVEO’s pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the initiation of a phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO’s earlier stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb).
On January 19, 2023, AVEO Oncology was acquired by LG Chem, Ltd. (“LG Chem”), expanding LG Chem’s Life Sciences’ oncology portfolio. AVEO now operates as an LG Chem company, leveraging the companies’ combined capabilities to deliver continued progress across clinical and pre-clinical stage anti-cancer therapies and accelerating the commercialization of new anti-cancer drugs developed by LG Chem.
Together, AVEO and LG Chem seek to become a global oncology organization with a robust portfolio of innovative products and deep capabilities from discovery to clinical, biologics manufacturing and U.S. commercialization, at a scale capable of delivering on its mission to improve the lives of patients with cancer.
Bringing together AVEO and LG Chem provides significant momentum for AVEO to evolve to the next level: a global top 20 oncology leader in the next 5 years.
About LG Chem and LG Chem Life Sciences
LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. LG Chem manufactures a wide range of products from high-value-added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers. www.lgchem.com
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing and commercialization pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make a global presence by focusing on key core therapeutic areas of Oncology, Immunology and Metabolic Diseases. For more information, please visit LG Chem Life Science Introduction Page.
FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2
For more information, please visit FOTIVDA
Ficlatuzumab, AV-203, AV-380 and AV-353 are investigational drugs and have not yet been approved by the U.S. Food and Drug Administration (FDA).
1Fotivda (Tivozanib) SmPC August 2017
2Motzer RJ, Nosov D, Eisen T, et al. J Clin Oncol 2013; 31(30): 3791-9